Nanexa Soared 114% on a Novo Nordisk License: What the $1.33 Billion Actually Means
Nanexa shares soared on September 25, 2026, after a deal with Novo Nordisk covering injection technology worth up to about €1.17 billion ($1.33 billion). AOL
Reporting on the same date put the gain at 114% and described the deal as a licensing deal, in simple terms permission to use Nanexa's technology in return for payments. Investing.com The two reports cover the same event on the same day, one focusing on the share-price jump and the other on the headline value.
The technology involved is PharmaShell, Nanexa's system using atomic layer deposition (ultra-thin, layer-by-layer coating) to make long-acting formulations, drugs designed to release slowly over time. Nanexa The September 2026 reports identify the Novo Nordisk deal as centered on injection technology, which puts that coating-based platform at the center of the license.
Nanexa had previously announced an exclusivity and evaluation agreement worth SEK 46.1 million and a directed share issue, a sale of new shares straight to a chosen investor, of SEK 17.2 million to Novo Nordisk. Nanexa That announcement was dated December 21, 2022. It set up both a fixed payment for testing work and a direct ownership link well before the September 2026 license report.
The broader context here is the structure behind an "up-to" number. Headline license values add together firm payments and contingent, or if-then, payments. The €1.17 billion headline is conditional. What decides how much cash actually arrives is payment timing, what triggers each payment, who pays scale-up costs, and how royalties are calculated. Until those terms are disclosed, the €1.17 billion works as a cap on the contract, not as cash in the bank.
In my view, the move from testing to licensing is the operational detail to focus on. Evaluation agreements buy data and choice. They pay for specific technical work while letting the larger company decide whether to go ahead, expand, or walk away. A directed share sale alongside that work aligns interests and brings validation from the partner's balance sheet, but it also concentrates Nanexa's technical and commercial exposure. For a delivery platform, moving to a full license shifts the risk from whether it works in principle to whether it can be manufactured reliably, with consistent results from the coating process and smooth integration into fill-finish for long-acting injectables.
Looking at what this means for pricing, the 114% jump is a repricing of the odds, not the arrival of the full headline sum. Small drug-delivery stocks trade on expected milestone payments, adjusted for risk and discounted for failure rates, long timelines, and reliance on one big partner. A license with a large drugmaker reduces the discount for technical doubt while making Nanexa more sensitive to development decisions outside its control. The earlier SEK 46.1 million evaluation payment and SEK 17.2 million share sale are the only disclosed guide to firm committed money in this relationship. Everything above that is contingent.
